Argenx scraps Vyvgart Sjogren’s study after monitoring committee deems futile
Argenx said an independent monitoring committee indicated its Vyvgart study in Sjogren’s disease appeared futile, leading it to scrap the study. The stock fell about 11% in morning trading.